Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

spa industries global pty ltd - hydrogen peroxide - liquid - hydrogen peroxide ungrouped active 150.0 g/l - pool sanitiser - spa | outdoor spa | spa pools - bacteria

European Union - English - EMA (European Medicines Agency)

baxalta innovations gmbh - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leukemia, myeloid, acute - antineoplastic agents - xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.,

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - pegaspargase, quantity: 750 u/ml - solution, powder for - excipient ingredients: sucrose; dibasic sodium phosphate; monobasic sodium phosphate; sodium chloride; sodium hydroxide; hydrochloric acid - oncaspar is indicated as a component of antineoplastic combination therapy in patients with acute lymphoblastic leukaemia (all).

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - gilteritinib fumarate (unii: 5rzz0z1gjt) (gilteritinib - unii:66d92mgc8m) - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a fms-like tyrosine kinase 3 (flt3) mutation as detected by an fda-approved test. xospata is contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients. anaphylactic reactions have been observed in clinical trials [see adverse reactions (6) and description (11)] . risk summary based on findings from animal studies (see data) and its mechanism of action, xospata can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on xospata use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, administration of gilteritinib to pregnant rats during organogenesis caused adverse developmental outcomes including embryo-fetal lethality, suppressed fetal growth, and teratogenicity at maternal exposures (auc24 ) approximately 0.4 times the auc

Israel - English - Ministry of Health

astellas pharma international b.v., israel - gilteritinib as fumarate - film coated tablets - gilteritinib as fumarate 40 mg - gilteritinib - xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pool ranger pty limited - refer to label - granular formulation - refer to label misc active 0.0 undefined - pool chlorine - spa | swimming pool | outdoor spa | spa pools - bacteria | protozoa | virus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

hy-clor (australia) pty ltd - bromine present as bromo-chloro-dimethylhydantoin; chlorine present as bromo-chloro-dimethylhydantoin - tablet (inc. pellet, bolus, suppository, capsule) - bromine present as bromo-chloro-dimethylhydantoin mineral-bromine active 650.0 g/kg; chlorine present as bromo-chloro-dimethylhydantoin mineral-chlorine active 280.0 g/kg - pool algicide - indoor pool | spa | outdoor spa | spa pools - algae | bacteria

Australia - English - Department of Health (Therapeutic Goods Administration)

the royal children's hospital - monosodium aspartate, quantity: 1.4 mmol/ml - injection, concentrated - excipient ingredients: water for injections - substrate for organ perfusion.